BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 25520039)

  • 1. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma: is immunotherapy of benefit?
    Faries MB; Morton DL
    Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
    [No Abstract]   [Full Text] [Related]  

  • 3. Melanoma in situ: Part II. Histopathology, treatment, and clinical management.
    Higgins HW; Lee KC; Galan A; Leffell DJ
    J Am Acad Dermatol; 2015 Aug; 73(2):193-203; quiz 203-4. PubMed ID: 26183968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
    Shah DJ; Dronca RS
    Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous melanoma: detecting it earlier, weighing management options.
    Lane JE; Dalton RR; Sangueza OP
    J Fam Pract; 2007 Jan; 56(1):18-28. PubMed ID: 17217894
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in the treatment of cutaneous melanoma?
    Olhoffer IH; Bolognia JL
    Semin Cutan Med Surg; 1998 Jun; 17(2):96-107. PubMed ID: 9669603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of melanoma.
    Brown CK; Kirkwood JM
    Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma: from darkness to promise.
    Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
    Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications and options for systemic therapy in melanoma.
    Sondak VK; Gibney GT
    Surg Clin North Am; 2014 Oct; 94(5):1049-58, viii. PubMed ID: 25245967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous melanoma: available therapy for metastatic disease.
    Tarhini AA; Agarwala SS
    Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for cutaneous melanoma.
    Treisman J; Garlie N
    Clin Plast Surg; 2010 Jan; 37(1):127-46. PubMed ID: 19914464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.